Abstract
The aim of this study was to evaluate the influence of leukocyte nitric oxide (NO) production on the antiplatelet aggregant effect of aspirin and ticlopidine. This in vitro study was done with platelets (platelet-rich plasma, PRP) and polymorphonuclear leukocytes (PMNLs) separated from samples of human blood. Collagen-induced platelet aggregation and calcium-dependent NO production by PMNL were quantified. The inhibition of NO production in PRP significantly reduced the antiaggregant affect of aspirin (IC 50 2.64-fold greater), whereas it had no significant effect on the effect of ticlopidine (IC 50 1.03-fold greater). Incubating PMNL in PRP increased the antiaggregant effect of both aspirin (IC 50 5.09-fold lower) and ticlopidine (IC 50 10.16-fold lower). The inhibition of NO production in PMNL significantly reduced the antiaggregant effect of both aspirin (IC 50 2.21-fold greater) and ticlopidine (IC 50 3.26-fold greater). Both drugs increased leukocyte NO production. The concentration of aspirin that raised NO production by 50% was greater than 1000 μM, whereas the concentration of ticlopidine that led to this effect was 9.14±0.87 μM. We conclude that the effect of ticlopidine on leukocyte NO production may constitute an addition mechanism to the IIb/IIIa glycoprotein complex inactivation in the inhibition of platelet activation.
Paper version not known (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call